Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder

Lilly

Status and phase

Completed

Phase 4

Conditions

Schizophrenia

Schizoaffective Disorder

Treatments

Drug: Olanzapine

Study type

Interventional

Funder types

Industry

Identifiers

NCT00100776

F1D-US-HGLF

8333

Details and patient eligibility

About

The purposes of this study are to assess the efficacy, safety, and side effects among doses approved by the Food and Drug Administration and higher (not FDA approved) doses of olanzapine in patients with schizophrenia or schizoaffective disorder.

Sex

All

Ages

18 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

You must be 18 to 60 years old
You must have been diagnosed with schizophrenia or schizoaffective disorder
You must be able to visit the doctor's office 8 times over a 9 week period
You must agree to participate with all tests and examinations that are required for this study

Exclusion criteria

You are a woman and are pregnant or breastfeeding
You presently have an acute or unstable medical illness
You have a history of an allergic reaction to olanzapine
You are taking medications that are not permitted in this study. Your physician will discuss these with you
You have taken part in another clinical research trial within the last 30 days or you have received treatment with a drug in the last 30 days that has not received regulatory approval.